Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCOA1 | Q15788 | 1/20 | 0.41 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.36 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.36 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13915601 | 0.87 | LMNA (0.42) | NCOA1NCOA3MAOAALDH1A1RAB9A | |
| SCHEMBL13915604 | 0.84 | ALDH1A1 (0.51) | NCOA1NCOA3MAOAALDH1A1RAB9A | |
| SCHEMBL12426828 | 0.82 | PPARA (0.45) | ALDH1A1RAB9ANPC1MAPK1MAPT | |
| SCHEMBL5076721 | 0.82 | HSPB1 (0.42) | ALDH1A1RAB9ANPC1MAPK1MAPT | |
| SCHEMBL13915602 | 0.81 | NCOA1 (0.41) | NCOA1NCOA3MAOAALDH1A1RAB9A | |
| SCHEMBL5137765 | 0.76 | NCOA1 (0.40) | NCOA1NCOA3ALDH1A1RAB9AMAPT | |
| SCHEMBL13915605 | 0.76 | SSTR4 (0.43) | NCOA1NCOA3MAPTHTTKDM4E | |
| SCHEMBL3484675 | 0.75 | RIPK1 (0.41) | MAPK1MAPTHPGDLMNACYP3A4 | |
| SCHEMBL13915668 | 0.75 | MTNR1B (0.37) | NCOA1NCOA3ALDH1A1RAB9ANPC1 | |
| SCHEMBL13915663 | 0.74 | PPID (0.48) | MAOAALDH1A1RAB9ANPC1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1664051-A4 | PYRROLOPYRIDAZINE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | BRISTOL MYERS SQUIBB CO (US) | 2008-12-31 | — | — | EP | disclosed |
| EP-1664051-A2 | PYRROLOPYRIDAZINE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Bristol-Myers Squibb Company (US) | 2006-06-07 | — | — | EP | disclosed |
| US-7030112-B2 | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-04-18 | — | — | US | disclosed |
| WO-2005030144-A2 | PYRROLOPYRIDAZINE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20040209886-A1 | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209886-A1 | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders | PCNA, DPYD, MALT1 | NCOA1 1648/4885NCOA3 1595/4885MAOA 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.